Nov. 30, 2022—A Vanderbilt study found that higher levels of excess oxygen given to patients under general anesthesia add risk of injury to the kidneys, lungs and heart.
Nov. 17, 2022—Vanderbilt researchers have received three grants totaling $13.6 million from the National Institutes of Health to develop molecular “atlases” of the brain, kidney, eye and other tissues.
Nov. 17, 2022—An in-depth analysis by Vanderbilt investigators of published research studies supports removing race from the calculation of estimated glomerular filtration rate (eGFR) — an assessment of kidney function.
Nov. 17, 2022—Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis
Nov. 16, 2022—Researchers from from Vanderbilt-Ingram Cancer Center have identified the mechanism for the deadly heart inflammation myocarditis.
Nov. 10, 2022—Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.
Nov. 10, 2022—VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity.
Nov. 8, 2022—Vanderbilt researchers found that a protein with roles in innate immunity worsens memory at baseline in carriers of APOE-e4, the strongest genetic risk factor for Alzheimer’s disease, further implicating neuroinflammation in cognitive decline.